Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive‐disease small cell lung cancer in the elderly and patients with poor performance status

Carboplatin plus etoposide (CE) is a standard treatment for elderly patients with extensive‐disease small cell lung cancer (ED‐SCLC). However, amrubicin monotherapy (AMR) may be a feasible alternative. We compared the efficacies and safety profiles of CE and AMR for ED‐SCLC in elderly patients and chemotherapy‐naive patients with poor performance status (PS).

[1]  T. Tamura,et al.  A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients , 2017, Cancer Chemotherapy and Pharmacology.

[2]  K. Kaira,et al.  Clinical significance of post‐progression survival in lung cancer , 2017, Thoracic cancer.

[3]  M. Yamada,et al.  Clinical impact of post‐progression survival on overall survival in elderly patients with extensive disease small‐cell lung cancer , 2016, Thoracic cancer.

[4]  H. Ohmatsu,et al.  Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer. , 2015, Japanese journal of clinical oncology.

[5]  B. Han,et al.  Current small cell lung cancer treatment in China , 2015, Thoracic cancer.

[6]  Yuankai Shi,et al.  Medical management of lung cancer: Experience in China , 2015, Thoracic cancer.

[7]  Y. Ichinose,et al.  A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). , 2014, Lung cancer.

[8]  M. Shibuya,et al.  A randomized phase III study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer. , 2014, Clinical lung cancer.

[9]  Jan P van Meerbeeck,et al.  Small-cell lung cancer , 1980, The Lancet.

[10]  H. Ohmatsu,et al.  Severe Interstitial Lung Disease Associated with Amrubicin Treatment , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Y. Tomizawa,et al.  A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. , 2010, Lung cancer.

[12]  K. Katono,et al.  Amrubicin for treating elderly and poor-risk patients with small-cell lung cancer , 2010, International Journal of Clinical Oncology.

[13]  F. Hommura,et al.  Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Tsukuma,et al.  Trends in Lung Cancer Incidence by Histological Type in Osaka, Japan , 2008, Japanese journal of clinical oncology.

[15]  Yukiko Nakamura,et al.  Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third-Line Chemotherapy for Small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  N. Saijo,et al.  Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 , 2007, British Journal of Cancer.

[17]  M. Fukuoka,et al.  Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study , 2007, Investigational New Drugs.

[18]  K. Uematsu,et al.  Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Saijo,et al.  Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  I. Okamoto,et al.  Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer , 2006, Cancer Chemotherapy and Pharmacology.

[21]  Tomoyuki Watanabe,et al.  Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs , 2004, Investigational New Drugs.

[22]  T. Morita.  A Statistical Study of Lung Cancer in the Annual of Pathological Autopsy Cases in Japan, from 1958 to 1997, with Reference to Time Trends of Lung Cancer in the World , 2002, Japanese journal of cancer research : Gann.

[23]  E. Lemarié,et al.  Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Satoko Mizuno,et al.  A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex , 1998, Japanese journal of cancer research : Gann.

[25]  A. Coldman,et al.  Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Yamaoka,et al.  Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells , 1998, Japanese journal of cancer research : Gann.

[27]  R. Souhami,et al.  Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. , 1997, Journal of the National Cancer Institute.

[28]  S. Dahrouge,et al.  Oral Etoposide and Carboplatin: Effective Therapy for Elderly Patients with Small Cell Lung Cancer , 1995, American journal of clinical oncology.

[29]  Y. Kashiwazaki,et al.  Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts , 1989, Japanese journal of cancer research : Gann.

[30]  N. Ohashi,et al.  Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds , 1987 .